Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real-World Comparative Effectiveness Research and Related Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients Using Oral Anti-coagulants

Trial Profile

Real-World Comparative Effectiveness Research and Related Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients Using Oral Anti-coagulants

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Nov 2018

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
  • Indications Embolism
  • Focus Adverse reactions
  • Acronyms ARISTOPHANES
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 14 Nov 2018 Results of a sub-group analysis presented at the 91st Annual Scientific Sessions of the American Heart Association.
    • 14 Nov 2018 Results from a sub-group analysis presented at the 91st Annual Scientific Sessions of the American Heart Association
    • 11 Nov 2018 According to a Bristol-Myers Squibb media release, real-world evidence (RWE) from a sub-analysis of this trial was presented at the American Heart Association Scientific Sessions 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top